Early and Sustained LDL-C Reduction with Inclisiran in High-Risk Cardiovascular Patients

Recent findings from the VICTORION-Difference trial demonstrate that inclisiran, administered via subcutaneous injections every three or six months, effectively achieves early and persistent reductions in low-density lipoprotein cholesterol (LDL-C) levels in patients at high or very high risk for cardiovascular events. The study, presented at ESC Congress 2025, involved 1,770 participants across Europe who had elevated LDL-C despite optimized lipid-lowering treatment. Participants received either inclisiran or placebo alongside standard therapy, including open-label rosuvastatin titrated to maximum tolerated doses.

Results showed that a significantly greater proportion of the inclisiran group attained their LDL-C targets at 90 days—84.9% compared to 31.0% in the placebo group, illustrating the drug's superior efficacy. Over a 12-month period, inclisiran reduced LDL-C levels by approximately 59.45%, markedly outperforming the 24.31% reduction seen with standard care alone. Importantly, the trial also reported fewer muscle-related adverse events in the inclisiran group (11.9%) compared to controls (19.2%).

Professor Ulf Landmesser, lead investigator, emphasized that inclisiran’s mechanism involves inhibiting PCSK9 production, which results in lower LDL-C levels. Its once or twice-yearly dosing makes it a practical option for long-term management, especially for patients who experience safety concerns or adherence issues with other therapies. Overall, the study highlights inclisiran’s potential to be a convenient, effective, and well-tolerated treatment for individuals struggling to meet LDL-C goals with existing medications, ultimately helping reduce the risk of cardiovascular disease.

Source: https://medicalxpress.com/news/2025-09-early-sustained-ldl-goal-inclisiran.html